BTK and rheumatoid arthritis: As a potent BTK inhibitor, ibrutinib exhibited therapeutic effects in both the collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA) rodent models of RA in a dose-dependent manner [29,30,31].